论文部分内容阅读
目的探讨孟鲁司特钠治疗儿童咳嗽变异性哮喘(CVA)的疗效及安全性。方法 74例患儿随机分为治疗组和对照组,每组37例,对照组给予特布他林雾化吸入,口服酮替芬;治疗组在对照组的基础上睡前服用孟鲁司特钠,比较2组临床疗效和安全性。结果治疗组总有效率(83.78%)明显高于对照组(64.86%)(P<0.05);治疗组症状改善时间明显低于对照组(P<0.05),治疗后血嗜酸性粒细胞(EOS)比例下降及最大呼气峰流速(PEF)升高值明显优于对照组(P<0.05)。治疗组复发率明显低于对照组(P<0.05)。结论孟鲁司特钠治疗CVA临床疗效明显,复发率低,不良反应少,值得推广应用。
Objective To investigate the efficacy and safety of montelukast sodium in the treatment of children with cough variant asthma (CVA). Methods 74 cases of children were randomly divided into treatment group and control group, 37 cases in each group, the control group was given inhalation of terbutaline, oral ketotifen; treatment group on the basis of the control group taking montelukast Sodium, the clinical efficacy and safety of two groups were compared. Results The total effective rate (83.78%) in the treatment group was significantly higher than that in the control group (64.86%) (P <0.05). The improvement time of the treatment group was significantly lower than that of the control group (P <0.05). After treatment, the blood eosinophils ) Decreased and the maximum peak expiratory flow rate (PEF) increased significantly higher than the control group (P <0.05). The recurrence rate of the treatment group was significantly lower than that of the control group (P <0.05). Conclusion Montelukast sodium treatment of CVA obvious clinical efficacy, low recurrence rate, fewer adverse reactions, it is worth promoting the application.